Clinical and Analytical Performance of DuritectTM: A Novel Blood-Based Autoantibody Diagnostic Sceening Platform for Alzheimer’s and Parkinson’s Diseases (P10-3.009)
In the present study we demonstrate the clinical and analytical utility of the Duritect™ platform, a diagnostic screening solution comprised of panels of customized blood-based autoantibody biomarkers capable of detecting disease-related processes resulting from ongoing Alzheimer’s or Parkinson’s disease pathology, using a proprietary risk score capable of predicting an individual’s likelihood of developing AD or PD in the future.
Authors
- Jeffrey Viviano (ORCID: https://orcid.org/0000-0003-2006-5306)
- Robert G. Nagele (ORCID: https://orcid.org/0000-0003-2691-4137)
- Cassandra DeMarshall
- Donna M. Hutchison (ORCID: https://orcid.org/0000-0002-5384-8561)
- Anuradha Krishnan (ORCID: https://orcid.org/0000-0001-9401-0776)
- Mehmet Şahin (ORCID: https://orcid.org/0000-0002-6400-8410)
Institutions
- Rowan University (US)
Publication Details
- Journal
- Neurology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1212/wnl.0000000000212002
- Primary Topic
- Advanced Biosensing Techniques and Applications
- Type
- article
- Field-Weighted Citation Impact
- 0.00